Uracil Mustard. 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione . Mustard, Uracil . Uramustine . Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. . 0.53
Nitrogen Mustard Compounds. Compounds, Nitrogen Mustard . Mustard Compounds, Nitrogen . A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens. . 0.39
Prednimustine. Leo-1031 . NSC-134087 . Sterecyt . Stereocyt . Stéréocyt . Leo 1031 . Leo1031 . NSC 134087 . NSC134087 . Ester of CHLORAMBUCIL and PREDNISOLONE used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. It causes gastrointestinal and bone marrow toxicity. . 0.39
Alkylating Agents. Alkylators . Agents, Alkylating . Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. . 0.38
Triaziquone. 2,3,5-Tris(ethyleneimine)benzoquinone . Trenimon . Alkylating antineoplastic agent used mainly for ovarian tumors. It is toxic to skin, gastrointestinal tract, bone marrow and kidneys. . 0.37
Antineoplastic Agents, Alkylating. Alkylating Antineoplastic Agents . Alkylating Antineoplastic Drugs . Alkylating Antineoplastics . Alkylating Drugs, Antineoplastic . Antineoplastic Alkylating Agents . Antineoplastic Drugs, Alkylating . Antineoplastics, Alkylating . Antineoplastic Alkylating Drugs . Drugs, Antineoplastic Alkylating . Alkylating Agents, Antineoplastic . A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) . 0.37
